Skip to main content
OpenTrials
Completed

NCT Number: NCT02282319

Spinal or Intravenous Dexmedetomidine in Ambulatory Surgery

The primary objective of this double blind randomized study is to determine the effect of dexmedetomidine on onset and duration of the sensory and motor block and on the influence on bladder function after spinal anesthesia with chloroprocaine. Our primary hypothesis is that sensory block will significantly be prolonged by dexmedetomidine administered by both the spinal and the intravenous route. The investigators do not expect a significant difference in motor block duration between intravenous or spinal administration. Secondary outcomes are micturition problems, duration of analgesia and the occurrence of side effects such as sedation and hypotension.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

University Hospital Antwerp, Antwerp, Belgium

Loading trial locations.

About this study

The study is designed as a multicenter study and randomization and inclusion of patients will be performed in three hospitals. Each hospital has its own randomisation sequence and coordinating investigator who will be responsible for appointing blinded and unblinded participators in the study.

Patients scheduled for spinal anesthesia in ambulatory surgery will be randomized by sealed envelopes (computer generated sequence) into one of the following three study groups:

spinal chloroprocaine 40 mg with spinal dexmedetomidine (5mcg) spinal chloroprocaine 40 mg with intravenous dexmedetomidine ( 0.5 mcg/kg) spinal chloroprocaine 40 mg alone (control group)

All patients will receive the same amount of spinal solution, containing chloroprocaine 1% (4 ml) with dexmedetomidine (0.5 ml, 1 mcg/ml) or NaCl ( sodiumchloride) 0,9% (0.5 ml ) ( and 50 ml intravenous Nacl 0.9, containing dexmedetomidine (0.5 mcg/kg) or not depending on the study group. All solutions are prepared by an independent anesthesiologist and labelled as Intravenous study medication and spinal study medication. Spinal anesthesia and data registration will be done by a blinded anesthesist and/or study nurse on a data sheet designed for the study.

Spinal anesthesia is performed in the lateral decubitus at L3-L4 vertebral interspace and standard monitoring for this procedure is applied. Insufficient analgesia will be treated with sufentanil increments. Hypotension and bradycardia will be treated with ephedrine and atropine. Patients will be discharged when the block is regressed, there is no sedation or nausea and nrs scores of pain are below 4. Patients will be contacted by telephone after one week to evaluate any postoperative complaints.Micturition will receive a score based on bladder volumes measured by bladder scanning and subjective complaints . This score system was used in two of our former studies (1,2)

To calculate the power of this study, we used the mean L2 regression of a previous study after spinal chloroprocaine with its standard deviation (SD 20 min, mean 90 min) and compared it to a mean increase with 30 %. We calculated that we should include 7 patients in each group to obtain a power of 80%.

To be sure to detect a possible difference in discharge time as well, we calculated a sample size of 48 patients for each group to detect a 30-minute difference.

Statistical analysis will be done with ANOVA analysis , A kruskal-Wallis of Mann Whitney test depending on the distribution of the population and if the values are parametric or not. This will be done by spss.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • ASA (American Society of Anesthesiologists) class 1 & 2,
  • undergoing day-case knee arthroscopy

Exclusion criteria

  • micturition problems,
  • neurological history or
  • previous lower abdominal surgery with an abnormal micturition

Treatment and study plan

spinal dexmedetomidine 0.5 mcg

Drug

Administration of dexmedetomidine 0.5 mcg

Other names: dexdor

spinal chloroprocaine 40 mg

Other

spinal anesthesia with chloroprocaine 40 mg

Other names: ampres

IV dexmedetomidine 0.5 mcg/kg

Drug

intravenous administration of dexmedetomidine 0.5 mcg/kg

Other names: dexdor

Primary outcomes

  1. sensory block regression L2 dermatome (minutes) (Time from injection until First time registration of loss of cold sensation)

    Time frame: up to 360 minutes

    Time from injection until First time registration of loss of cold sensation at the L2 dermatome during block regression. Loss of cold sensation will be regularly assessed from spinal injection until total regression of the sensory block

  2. Motor block regression (minutes) (time from injection until achievement of active knee movement)

    Time frame: up to 240 minutes

    time from injection until achievement of active knee movement during block regression. Motor block will be assessed at regular intervals from spinal injection untill total regression of the motor block

Secondary outcomes

  1. discharge time (minutes)

    Time frame: up to 240 minutes

    time from spinal injection until achievement of discharge criteria

  2. time to micturition ( minutes)

    Time frame: up to 240 minutes

    time from injection until first voiding

  3. blood pressure drop

    Time frame: up to 240 minutes

    percentage of drop blood pressure compared to base line ( measured before spinal injection) . Blood pressure will be measured at regular intervals from just prior to spinal injection until discharge

Other outcomes

  1. micturition problems (scaling based on bladder volumes and subjective difficulties) in a 1-5 point scale

    Time frame: at discharge ( up to 240 minutes)

    classification of problems ( scaling based on bladder volumes and subjective difficulties) in a 1-5 point scale

Sponsors and collaborators

Lead sponsor

University Hospital, Antwerp

Other

Registry information

Official study title

Influence of Spinal or Intravenous Dexmedetomidine on Spinal Anesthesia With Chloroprocaine and Bladder Function in Day-case Surgery. A Double Blind Randomized Study.

Important dates

Study start
2014
Primary completion
2020
Study completion
2020
First posted
Nov 4, 2014
Registry last updated
Aug 5, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.